Status:
COMPLETED
Donor Dopamine and Initial Graft Function
Lead Sponsor:
Universitätsmedizin Mannheim
Collaborating Sponsors:
Eurotransplant International Foundation, Leiden, The Netherlands
Regional Organ Procurement Organization (DSO), Baden-Wuerttemberg, Germany
Conditions:
Kidney Transplantation
ESRD
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Donor pre-treatment with dopamine reduces injury to the kidney graft with consequences on the clinical performance immediately after transplantation: Donor dopamine reduces the requirement of dialysis...
Detailed Description
During the transplantation process, the kidney graft is exposed to numerous events which may in turn lead to function deteriorations. In particular, factors related with brain death, like hemodynamic ...
Eligibility Criteria
Inclusion
- Donors:
- Brain death confirmed
- Given consent to organ donation
- Current s-creatinine \< 2mg/dl
- On admission s-creatinine \< 1.3mg/dl
- Recipients:
- Age over 18 years
- Placed on the waiting list
- Organ allocation according to ET standards
Exclusion
- Donors:
- Application of dopamine/dobutamine/adrenaline
- Application of noradrenaline \> 0.4µg/kg\*min
- Hemodynamic instability
- Recipients:
- Refusal to participate in study /data analysis
- Pregnancy
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
487 Patients enrolled
Trial Details
Trial ID
NCT00115115
Start Date
March 1 2004
End Date
March 1 2009
Last Update
April 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Mannheim
Mannheim, Baden-Wurttemberg, Germany, 68135